PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast - Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

04/21/21 • 76 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

Previous Episode

undefined - Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum

Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum

Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.

Next Episode

undefined - Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.